# WIA-BIO-020 — Phase 2: API Interface

> Regenerative-medicine canonical Phase 2: API surface (preparations + factors + applications + audit + adverse-events + cleanroom).

# WIA-BIO-020: Regenerative Medicine Specification v1.0

> **Standard ID:** WIA-BIO-020
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Regenerative Medicine Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Stem Cell Types and Classification](#2-stem-cell-types-and-classification)
3. [Regeneration Mechanisms](#3-regeneration-mechanisms)
4. [Tissue Engineering and Scaffolds](#4-tissue-engineering-and-scaffolds)
5. [Growth Factor Delivery Systems](#5-growth-factor-delivery-systems)
6. [Clinical Applications](#6-clinical-applications)
7. [Regulatory Requirements](#7-regulatory-requirements)
8. [Implementation Guidelines](#8-implementation-guidelines)
9. [Safety Protocols](#9-safety-protocols)
10. [References](#10-references)

---


## 8. Implementation Guidelines

### 8.1 Required Components

Any WIA-BIO-020 compliant system must include:

1. **Cell Source Management**: Track origin, passage, characterization
2. **Differentiation Protocols**: Standardized, validated methods
3. **Quality Control**: Real-time monitoring and testing
4. **Growth Factor Calculator**: Optimize dosing and timing
5. **Scaffold Designer**: Material, porosity, mechanics optimization
6. **Clinical Tracker**: Patient outcomes and safety monitoring

### 8.2 API Interface

#### 8.2.1 Calculate Regeneration Rate
```typescript
interface RegenerationRequest {
  tissueType: 'cardiac' | 'neural' | 'bone' | 'cartilage' | 'skin';
  cellDensity: number;      // cells/ml
  timeFrame: number;        // days
  growthFactors: string[];
}

interface RegenerationResponse {
  rate: number;             // cells/day
  recoveryPercentage: number;
  timeToComplete: number;   // days
  feasibility: 'high' | 'medium' | 'low';
}
```

#### 8.2.2 Assess Cell Survival
```typescript
interface SurvivalRequest {
  cellType: string;
  viableCells: number;
  totalCells: number;
  cultureConditions: string;
}

interface SurvivalResponse {
  survivalRate: number;     // 0-100%
  viability: 'excellent' | 'good' | 'fair' | 'poor';
  recommendations: string[];
}
```

#### 8.2.3 Design Scaffold
```typescript
interface ScaffoldRequest {
  tissueType: string;
  material: string;
  porosity: number;         // 0-1
  size: number;             // cm³
  mechanicalRequirements: {
    youngModulus?: number;  // MPa or GPa
    compressiveStrength?: number;
  };
}

interface ScaffoldResponse {
  design: {
    material: string;
    dimensions: { width: number; height: number; depth: number };
    poreSize: number;       // μm
    porosity: number;
    degradationTime: number; // months
  };
  mechanical: {
    youngModulus: number;
    tensileStrength: number;
    compressiveStrength: number;
  };
  biocompatibility: 'excellent' | 'good' | 'acceptable';
}
```

### 8.3 Data Formats

#### 8.3.1 Cell Characterization
```json
{
  "cellType": "iPSC",
  "passage": 15,
  "markers": {
    "OCT4": 0.95,
    "NANOG": 0.92,
    "SSEA4": 0.94
  },
  "viability": 0.89,
  "karyotype": "46,XY",
  "mycoplasma": "negative",
  "doubling_time_hours": 24
}
```

#### 8.3.2 Tissue Regeneration
```json
{
  "tissue": "cardiac",
  "patient_id": "P12345",
  "baseline": {
    "ejection_fraction": 0.35,
    "infarct_size_cm2": 15
  },
  "post_treatment": {
    "ejection_fraction": 0.42,
    "infarct_size_cm2": 10,
    "vessel_density": 320
  },
  "improvement_percentage": 20
}
```

### 8.4 Error Handling

Standard error codes:

| Code | Meaning | Action |
|------|---------|--------|
| B001 | Cell contamination detected | Discard culture, decontaminate |
| B002 | Low viability (<70%) | Optimize culture conditions |
| B003 | Marker expression insufficient | Extend culture, retest |
| B004 | Scaffold degradation too fast | Change material or crosslinking |
| B005 | Growth factor instability | Add stabilizers, reduce temperature |
| B006 | Immune rejection risk | HLA matching, immunosuppression |

---




---

## A.1 Endpoint reference

```http
POST /regenerative-medicine/v1/preparations          # register cell preparation
GET  /regenerative-medicine/v1/preparations/{id}     # fetch preparation record
POST /regenerative-medicine/v1/factors               # register growth factor
POST /regenerative-medicine/v1/applications          # register clinical application
GET  /regenerative-medicine/v1/audit/{prepId}        # audit trail
POST /regenerative-medicine/v1/qc-results            # contribute QC measurement
GET  /regenerative-medicine/v1/safety/incidents      # adverse-event log
WS   /regenerative-medicine/v1/cleanroom/stream      # cleanroom telemetry
```

Every endpoint follows the discovery convention at `/.well-known/wia-regenerative-medicine`.

## A.2 Preparation-record API

`POST /preparations` accepts the Phase 1 §A.1 envelope and returns a stable `prepId`. The endpoint is gated by an institutional credential issued to a clinical-grade cell-therapy facility with the appropriate scope; preparations intended for clinical use require the GMP-facility envelope and the regulatory-classification envelope. Read endpoints expose the per-batch lot-release record and the chain-of-custody graph from donor to administered dose.

## A.3 Quality-control API

`POST /qc-results` accepts a quality-control measurement against a preparation record per Phase 1 §A.5. The endpoint accepts the binary measurement payload (immunophenotyping FCS, karyotype image, qPCR plate, potency-assay reading) plus the analyst signature and the calibration-record reference per ISO/IEC 17025. Results in the operator's release-test envelope are gated for release; out-of-spec results trigger an investigation event per the operator's release-control SOP.

## A.4 Adverse-event API

`GET /safety/incidents` returns the de-identified adverse-event log filtered by indication, preparation type, and date range, with the FAERS-style narrative summarisation for tracked tumourigenicity / immunogenicity / acute-infusion / off-target-engraftment events. Subject-identifying fields are projected out unless the requesting credential carries the subject-data scope. Adverse events are reported to the controlling regulator per the documented timelines (FDA IND safety reporting per 21 CFR 312.32; EU CTR reporting per Regulation 536/2014; KFDA KGCP equivalents).

## A.5 Cleanroom telemetry WebSocket

The cleanroom-stream WebSocket multiplexes per-suite environmental events: HEPA-filter pressure differential, particle-count per ISO 14644 Class A/B/C/D, viable-air-monitor read-back, surface-monitoring read-back, glove-port leak-test status, and the operator-of-record envelope for each shift. Subscribers can filter by suite-id and by event class. The broker emits alarm events on out-of-band readings (particle excursion, pressure-cascade reversal) within the safety-loop's hard time budget.

## A.6 Rate-limit and rights envelope

Read endpoints: 100 req/h unauthenticated (read-only on de-identified data), 1000 req/h authenticated, 5000 req/h premium tier. Subject data-access requests follow the GDPR Article 15 protocol with a 30-day SLA; rectification (Article 16) and erasure (Article 17, where applicable) requests follow the documented exceptions for clinical-research records subject to retention obligations.

## A.7 Webhook delivery for QC and adverse-event lifecycle

Operators registered as cell-therapy facilities, regulatory inspectors, or partnered Tier-1 contract development and manufacturing organisations (CDMOs) can subscribe to webhook deliveries on QC-result lifecycle events (in-spec, out-of-spec, investigation, closed) and on adverse-event lifecycle events (initial-report, follow-up, closed). Webhook payloads carry the same envelope shape as the API GET response, signed by the WIA tenant key.


---

## Z.1 Glossary, conformance, governance

A companion glossary at `https://wiastandards.com/regenerative-medicine/glossary/`
expands every term used throughout this Phase. The conformance
test suite at `https://github.com/WIA-Official/wia-regenerative-medicine-conformance`
walks every endpoint and protocol exchange. The reference container
at `wia/regenerative-medicine-host:1.0.0` ships every regenerative-medicine envelope and
endpoint with mock data so integrators can exercise the contract
before wiring real backends. The companion CLI at
`cli/regenerative-medicine.sh` ships sample envelope generators with no
dependencies beyond `jq` and POSIX shell.

## Z.2 Cross-standard composition (recap)

This Phase composes with WIA-OMNI-API for credential storage,
WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for
federation handshake, WIA-INTENT for workload intent declaration,
and (where personal data is processed) WIA Secure Enclave for
sealed-data envelopes. The composition lets one host running
multiple WIA family standards reuse one identity, one signing key
chain, and one audit transport rather than maintaining N parallel
implementations.

## Z.3 Implementation runbook

A first implementation typically follows: stand up the reference
container; run the conformance suite against it end-to-end;
replace the mock backend with a real backend one endpoint at a
time; wire audit-log replication out to the operations sink;
onboard a single trusted peer for federation; expand to multiple
peers; promote to production with the warning-envelope subscription
enabled and the runbook in §Z.5 followed.

## Z.4 Backwards-compatibility promise

Within the 1.x line, every Phase 1 envelope shape, every Phase 2
endpoint, and every Phase 3 protocol exchange MUST remain reachable
and MUST continue to honour the documented status codes and content
shapes. Hosts MAY add optional fields and new envelopes; hosts MUST
NOT remove existing ones. Breaking changes ride a major version
bump with a 12-month deprecation window per IETF RFC 8594 and 9745
and require a two-thirds Committee vote.

## Z.5 Closing implementer note

This Phase fits inside the WIA Standards four-Phase architecture:
Phase 1 envelopes are the wire-format contract; Phase 2 surfaces
them through HTTPS; Phase 3 wraps them in protocol exchanges that
cross trust boundaries; Phase 4 integrates with the broader
ecosystem. Regenerative-medicine deployments that follow this layering
inherit the per-Phase conformance gates and the cross-standard
composition behaviour described in Z.2.

弘益人間 — Benefit All Humanity.
